Indoco Remedies Limited will conduct an earnings conference call on July 28, 2026, to discuss the unaudited financial results for the quarter ended June 30, 2026. The meeting is scheduled to begin at 3:30 PM IST, providing investors and analysts with an opportunity to review the company's performance for Q1 FY2026-2027.

The announcement was made pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was submitted to the National Stock Exchange of India Limited and the Bombay Stock Exchange Limited for information and dissemination.

The conference call will be represented by key members of the company's leadership team. Attendees include Ms. Aditi Panandikar, Managing Director; Mr. Sundeep V. Bambolkar, Joint Managing Director; and Mr. Pramod Ghorpade, Chief Financial Officer.

Participants are encouraged to pre-register using the provided DiamondPass link to avoid waiting queues. The company has provided universal access numbers for domestic participants and international toll-free lines for investors in Hong Kong, Singapore, the USA, and the UK.

For further inquiries regarding the earnings call, stakeholders may contact representatives from Dolat Capital Market Pvt. Ltd., including Rashmi Shetty, Candice Pereira, and Zain Gulam Hussain.

Conference Call Details

Indoco Remedies has received EU GMP certification for its Goa manufacturing facility from the Malta Medicines Authority, confirming compliance with Good Manufacturing Practice requirements under the EC Directive. The certification follows an inspection of the solid oral dosage form plant (Plant I) conducted from November 19 to November 24, 2025. This approval enables the company to reinforce its commitment to delivering high-quality healthcare products to global markets.

The disclosure was made to the National Stock Exchange of India and Bombay Stock Exchange under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The inspection focused on the company's manufacturing capabilities and quality systems at the Goa unit.

Certification Details

The key details of the EU GMP certification are outlined below:

Management Commentary

Aditi Panandikar, Managing Director of Indoco Remedies, stated that compliance is a core value driving the company's quality systems. She emphasized that the approval reinforces the organization's commitment to delivering the highest quality healthcare to customers worldwide. The company operates 10 manufacturing facilities, including six for finished dosage forms and four for active pharmaceutical ingredients, supported by a research and development centre.